The standardization of the HER2 score and recent changes in therpeutic modalities points to che need for reevaluation of the role in recently diagnosed breast carcinoma. A multicenter, retrospective study of 1794 primary breast carcinoas diagnosed in Italy in 200/2001 and scored in HER2 four categories accordin to immunohistochemistry was conducted. Ductal histotpe, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. Her2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months , HER2 3+ status was associated with higher relapse rates in node-positive subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, expecially taxanes. The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HE2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score / Ménard, S; Balsari, A; Tagliabue, E; Camerini, T; Casalini, P; Bufalino, R; Castiglioni, F; Carcangiu, Ml; Gloghini, A; Scalone, S; Querzoli, P; Lunardi, M; Molino, A; Mandarã, M; Mottolese, M; Marandino, F; Venturini, M; Bighin, C; Cancello, G; Montagna, E; Perrone, F; DE MATTEIS, A; Sapino, A; Donadio, M; Battelli, N; Santinelli, A; Pavesi, L; Lanza, A; Zito, Fa; Labriola, A; Aiello, Ra; Caruso, M; Zanconati, Fabrizio; Mustacchi, Giorgio; Barbareschi, M; Frisinghelli, M; Russo, R; Carrillo, G; Omero, Group. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - STAMPA. - 19:(2008), pp. 1706-1712. [10.1093/annonc/mdn369]
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
ZANCONATI, FABRIZIO;MUSTACCHI, GIORGIO;
2008-01-01
Abstract
The standardization of the HER2 score and recent changes in therpeutic modalities points to che need for reevaluation of the role in recently diagnosed breast carcinoma. A multicenter, retrospective study of 1794 primary breast carcinoas diagnosed in Italy in 200/2001 and scored in HER2 four categories accordin to immunohistochemistry was conducted. Ductal histotpe, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. Her2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months , HER2 3+ status was associated with higher relapse rates in node-positive subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, expecially taxanes. The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HE2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
